218 related articles for article (PubMed ID: 26048187)
21. Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series.
Soyka M; Groß G
Am J Drug Alcohol Abuse; 2021 Sep; 47(5):599-604. PubMed ID: 34407703
[TBL] [Abstract][Full Text] [Related]
22. Rapid Transition to Buprenorphine in a Patient With Methadone-Related QTc Interval Prolongation.
Brogdon H; Facer KL; Cox EJ; Carlson RH; Wurzel JF
J Addict Med; 2022 Jul-Aug 01; 16(4):488-491. PubMed ID: 34864786
[TBL] [Abstract][Full Text] [Related]
23. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
[TBL] [Abstract][Full Text] [Related]
24. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
[TBL] [Abstract][Full Text] [Related]
25. Treating Opioid Dependence: Pain Medicine Physiology of Tolerance and Addiction.
James DL; Jowza M
Clin Obstet Gynecol; 2019 Mar; 62(1):87-97. PubMed ID: 30614846
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of buprenorphine dosage adequacy in opioid receptor agonist substitution therapy for heroin dependence: first use of the BUprenorphine-naloxone Dosage Adequacy eVAluation (BUDAVA) questionnaire.
D'Amore A; Romano F; Biancolillo V; Lauro G; Armenante C; Pizzirusso A; Del Tufo S; Ruoppolo C; Auriemma F; Cassese F; Oliva P; Amato P
Clin Drug Investig; 2012 Jul; 32(7):427-32. PubMed ID: 22559256
[TBL] [Abstract][Full Text] [Related]
27. Peripartum Anesthetic Management of the Opioid-tolerant or Buprenorphine/Suboxone-dependent Patient.
Pan A; Zakowski M
Clin Obstet Gynecol; 2017 Jun; 60(2):447-458. PubMed ID: 28426507
[TBL] [Abstract][Full Text] [Related]
28. Novel Uses of Methadone Under the "72-Hour Rule" to Facilitate Transitions of Care and Low-Dose Buprenorphine Induction in an Outpatient Bridge Clinic.
Shahlapour M; Singh S; Christine PJ; Laks J; Evans J; Farrell NM; Khan GK; Taylor JL; Rozansky H
J Addict Med; 2024 May-Jun 01; 18(3):345-347. PubMed ID: 38329815
[TBL] [Abstract][Full Text] [Related]
29. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
DiPaula BA; Menachery E
J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
[TBL] [Abstract][Full Text] [Related]
30. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.
Neumann AM; Blondell RD; Jaanimägi U; Giambrone AK; Homish GG; Lozano JR; Kowalik U; Azadfard M
J Addict Dis; 2013; 32(1):68-78. PubMed ID: 23480249
[TBL] [Abstract][Full Text] [Related]
31. [Analgesic management of acute pain in patients receiving methadone or buprenorphine].
Zinck L; Sonne NM; Madsen SL; Nikolajsen L
Ugeskr Laeger; 2015 Mar; 177(10):. PubMed ID: 25749118
[TBL] [Abstract][Full Text] [Related]
32. Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction.
Neumann AM; Blondell RD; Hoopsick RA; Homish GG
J Addict Dis; 2020; 38(1):33-41. PubMed ID: 31774028
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
Sekar V; Tomaka F; Lefebvre E; De Pauw M; Vangeneugden T; van den Brink W; Hoetelmans R
J Clin Pharmacol; 2011 Feb; 51(2):271-8. PubMed ID: 20421512
[No Abstract] [Full Text] [Related]
34. Induction of patients with moderately severe methadone dependence onto buprenorphine.
Glasper A; Reed LJ; de Wet CJ; Gossop M; Bearn J
Addict Biol; 2005 Jun; 10(2):149-55. PubMed ID: 16191667
[TBL] [Abstract][Full Text] [Related]
35. Transition From Methadone to Buprenorphine Using a Short-acting Agonist Bridge in the Inpatient Setting: A Case Study.
Callan J; Pytell J; Ross J; Rastegar DA
J Addict Med; 2020; 14(5):e274-e276. PubMed ID: 31977358
[TBL] [Abstract][Full Text] [Related]
36. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
[TBL] [Abstract][Full Text] [Related]
37. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
[TBL] [Abstract][Full Text] [Related]
38. A protocol to switch high-dose, methadone-maintained subjects to buprenorphine.
Levin FR; Fischman MW; Connerney I; Foltin RW
Am J Addict; 1997; 6(2):105-16. PubMed ID: 9134072
[TBL] [Abstract][Full Text] [Related]
39. Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.
Moody DE
Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):675-97. PubMed ID: 23537174
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.
Piske M; Thomson T; Krebs E; Hongdilokkul N; Bruneau J; Greenland S; Gustafson P; Karim ME; McCandless LC; Maclure M; Platt RW; Siebert U; Socías ME; Tsui JI; Wood E; Nosyk B
BMJ Open; 2020 Sep; 10(9):e036102. PubMed ID: 32912944
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
